Skip Navigation U.S. Department of Health and Human Services www.hhs.gov
Agency for Healthcare Research Quality www.ahrq.gov
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: https://info.ahrq.gov. Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to www.ahrq.gov for current information.

Table 14. Tumor Characteristics Predictive of Response or Survival Among EGFR-TK Inhibitor Studiesd

Characteristic Favorable Prognostic Factor No. of studies indicating an association with response References No. of studies indicating an association with survival References
Histologic type Adeno vs. non-adeno 10/17 13,25,29,42,48,49,70 4/4 25,38,42,57
  BAC vs. non-BAC 2/4 50,71    
  Adeno/BAC vs. adeno, non-BAC vs. other 2/2 53,56 1/1 56
  Papillary vs. non-papillary 1/1 72 1/1 72
Grade Well/moderately vs. poorly differentiated     2/2 54,73
Stromal invasion       1/1 73
Mucin production       1/1 73
Expression by IHC          
EGFR Low vs. high 4/12 25,31,50,52,65,72,74-79 3/4 25,50,73,74
HER2/erbB2 2+/3+ vs. 0/1+ 2/6 50,65,70,72,78,80 1/2 73,80
p-EGFR - - 0/4 52,65,72,76 0/1 81
p-Akt status Positive vs. negative 2/6 50-52,63,65,78 1/3 50,67,70
p-Erk/p-MAPK 2+/3+ vs. 0/1+ 3/6 50-52,63,65,76 1/1 73
p-STAT3   0/1 52    
P53   0/1 78    
Ki-67   1/1 65 2/2 65,73
CYFRA 21-1 > 3.5 ng/ml
vs. < or = 3.5 ng/ml
- -   1/2 46,67
EGFR mutation Mutation vs. wild type 19/23 13,21,42,48-51,66,70,82-93 7/11 13,42,50,66,67,70,87,89,92,93
KRAS mutation Mutation vs. wild type 1/3 21,36,89 0/2 89,94

d Results of multivariable analysis reported in preference to results of univariable analyses when both were available.

Abbreviations: Adeno = adenocarcinoma; Adeno/BAC = adenocarcinoma with bronchoalveolar carcinoma features; BAC = bronchoalveolar carcinoma; EGFR = epidermal growth factor receptor; EGFR-TK = epidermal growth factor receptor tyrosine kinase; IHC = immuno histochemistry; No. = number

Return to Document

The information on this page is archived and provided for reference purposes only.

 

AHRQ Advancing Excellence in Health Care